Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG2513 ELPIS trial of platinum-doublet chemotherapy with or without pembrolizumab in treatment-naive advanced non-small cell lung cancer with ECOG performance status 2
jRCT1031260577Phase 3Recruiting
- Sponsor
- Japan Clinical Oncology Group
- Start
- Oct 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab, carboplatin, pemetrexed and paclitaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Japan Clinical Oncology Group. Primary endpoint: Overall survival. Started Oct 2026; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1031260577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031260577.